TITLE:
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

CONDITION:
Rheumatoid Arthritis

INTERVENTION:
placebo

SUMMARY:

      This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in
      the treatment of Rheumatoid Arthritis (RA).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of RA.

          -  All subjects will be required to have been taking a stable dose of methotrexate.

          -  Active RA at screening defined as greater than or equal to 6 swollen joints.

          -  The presence of erosive disease

        Exclusion Criteria:

          -  Received any biologic agent (e.g., Enbrel, Remicade, Humira, Kineret) or Arava
             within 8 weeks before randomization; past use of these agents is allowed.

          -  Steroid use greater than 15 mg/day.

          -  Scheduled for surgery or joint replacement in the hands, wrists or feet.
      
